Papers/PMID:38980732
Sodium Bicarbonate Treatment and Clinical Outcomes in Chronic Kidney Disease with Metabolic Acidosis: A Meta-Analysis.
Clinical journal of the American Society of Nephrology : CJASN2024The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
sodium hydrogencarbonate — increases systolic blood pressure (setting unspecified)
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Finding“However, higher risk of elevated systolic BP was found with sodium bicarbonate treatment (SMD, 0.10; 95% CI, 0.01 to 0.20; P = 0.03).”
Quoted verbatim from Sodium Bicarbonate Treatment and Clinical Outcomes in Chronic Kidney Disease with Metabolic Acidosis: A Meta-Analysis.. - Study
- meta-analysis
- Population
- Patients with chronic kidney disease and metabolic acidosis in randomized controlled trials; control groups defined inconsistently across trials
Effect 0.1 standardised mean difference, 95% CI 0.01 to 0.2
Sodium Bicarbonate Treatment and Clinical Outcomes in Chronic Kidney Disease with Metabolic Acidosis: A Meta-Analysis.2024PMID:38980732Permalink